2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Myeloproliferative Disorders
6
Carcinoma, Non-Small-Cell Lung
5
Primary Myelofibrosis
4
Hematologic Neoplasms
4
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Hodgkin Disease
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Large B-Cell, Diffuse
2
Lung Neoplasms
2
Leukemia, Prolymphocytic, T-Cell
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Thrombocytosis
1
Solid Tumors
1
Sarcoma, Synovial
1
Sarcoma
1
Polycythemia Vera
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Liposarcoma, Myxoid
1
Leukemia, Plasma Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Surveys and Questionnaires
16
Bevacizumab
14
Cisplatin
12
Blood Specimen Collection
11
Drug Therapy
10
Standard of Care
9
Nivolumab
9
Gemcitabine
9
Cetuximab
7
pembrolizumab
6
Specimen Handling
6
S 1 (combination)
6
Endoscopic Mucosal Resection
6
Cyclophosphamide
6
atezolizumab
5
Sunitinib
5
Radiotherapy
5
Folfox protocol
5
Educational Status
5
Docetaxel
5
fludarabine
4
aldesleukin
4
Radiosurgery
4
Pemetrexed
4
Magnetic Resonance Spectroscopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
itacitinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled